Post-Acute Care among Older Adults with Stage I to III Colorectal Cancer.

Related Articles

Post-Acute Care among Older Adults with Stage I to III Colorectal Cancer.

J Am Geriatr Soc. 2018 Dec 03;:

Authors: Kenzik KM, Williams GR, Bhatia S, Balentine CJ

Abstract
BACKGROUND: Little information is available on the long-term use of post-acute care among older patients with colorectal cancer (CRC), relative to individuals without cancer. This study examines the use of post-acute care among older cancer survivors (>65 y) with CRC and compares it with noncancer patients up to 5 years from surgery.
DESIGN: Retrospective cohort.
SETTING: SEER-Medicare.
PARTICIPANTS: Patients treated for stage I to III CRC between January 1, 2000, and December 31, 2011 (n = 40 812) and noncancer Medicare beneficiaries hospitalized for noncancer treatment matching on age, sex, race, comorbidity, and Medicaid dual eligibility.
MEASUREMENTS: Incident post-acute care claims (skilled nursing, long-term care facility, and home health) from 0 to 100 days, 101 to 365 days, and 1 to 5 years from hospitalization.
RESULTS: The median age was 77 years. All patients had surgery, 34% received chemotherapy, and 27% received surgery and adjuvant therapy. The cumulative incidence of any post-acute care within 100 days of hospitalization was 45.7% for stage III, 37.9% for stage I/II, and 39% for controls (p < .001). Within the CRC cohort only, the cumulative incidence of post-acute care was 2.9% (stage I/II) and 4.2% (stage III, p < .001) from 101 to 365 days and 15.8% (stage I/II) and 16.9% (stage III, p < .001) from 1 to 5 years. Increasing age, ostomies, and neoadjuvant or adjuvant therapy were associated with increased hazard of all post-acute patients within 100 days from hospitalization. From 1 to 5 years from diagnosis, adjuvant therapy was associated with greater exclusive home health care use.
CONCLUSIONS: Survivorship planning among older CRC patients should include discussions of post-acute care following cancer therapy, even several years after treatment.

PMID: 30508295 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2QCe9pE